Semma Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Semma Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10995
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Semma Therapeutics Inc (Semma Therapeutics) is a biotechnology company that develops cell replacement therapy for the treatment of diabetes. The company develops therapies using stem cells of the individuals with Type 1 diabetes to produce their own insulin that will regulate the blood sugar levels. Semma’s regenerative medicine therapies and stem cell technologies with delivery systems are designed to protect cells from the immune system. The company focuses on combining active cells with a state-of-the-art cell delivery technology to cure patients with diabetes. It has offices in Cambridge and Providence, the US. Semma Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Semma Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Semma Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Semma Therapeutics Raises USD114 Million in Series B Financing 10
Semma Therapeutics Raises Funds through Venture Financing 12
Semma Therapeutics Raises USD44 Million in Series A Financing 13
Partnerships 14
Semma Therapeutics Enters into Agreement with Novartis 14
Licensing Agreements 15
Semma Therapeutics Enters into Licensing Agreement with Harvard University 15
Acquisition 16
Semma Therapeutics Acquires CytoSolv 16
Semma Therapeutics Inc – Key Competitors 17
Semma Therapeutics Inc – Key Employees 18
Semma Therapeutics Inc – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Corporate Communications 20
May 10, 2018: Semma Therapeutics Appoints Bastiano Sanna, Ph.D. as Chief Executive Officer and President 20
Other Significant Developments 21
Mar 22, 2017: Semma Therapeutics Receives Investment from JDRF T1D Fund 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Semma Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Semma Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Semma Therapeutics Raises USD114 Million in Series B Financing 10
Semma Therapeutics Raises Funds through Venture Financing 12
Semma Therapeutics Raises USD44 Million in Series A Financing 13
Semma Therapeutics Enters into Agreement with Novartis 14
Semma Therapeutics Enters into Licensing Agreement with Harvard University 15
Semma Therapeutics Acquires CytoSolv 16
Semma Therapeutics Inc, Key Competitors 17
Semma Therapeutics Inc, Key Employees 18
Semma Therapeutics Inc, Other Locations 19
Semma Therapeutics Inc, Subsidiaries 19

List of Figures
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Semma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Semma Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kyochon F&B Co., Ltd.:企業の戦略・SWOT・財務分析
    Kyochon F&B Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kyochon F&B Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Cadence Design Systems Inc (CDNS):企業の財務・戦略的SWOT分析
    Cadence Design Systems Inc (CDNS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Natural Alternatives International Inc (NAII):企業の財務・戦略的SWOT分析
    Summary Natural Alternatives International Inc (NAI) is a formulator and manufacturer of customized nutritional supplements. The company manufactures and distributes the only patented beta-alanine supplement on the market. It offers services such as science-based product formulation, raw material ac …
  • Simplex Infrastructures Ltd:企業の戦略・SWOT・財務情報
    Simplex Infrastructures Ltd - Strategy, SWOT and Corporate Finance Report Summary Simplex Infrastructures Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Civica Group Limited:企業の戦略的SWOT分析
    Civica Group Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • BHP:企業のM&A・事業提携・投資動向
    BHP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BHP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, …
  • TG Therapeutics Inc (TGTX):製薬・医療:M&Aディール及び事業提携情報
    Summary TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops and commercializes pharmaceutical products for the treatment of B-cell malignancies and autoimmune diseases. The company develops two therapies, namely, TG-1101 (ublituximab) and TGR-1202 for the tr …
  • The Binding Site Group Ltd:企業の製品パイプライン分析2018
    Summary The Binding Site Group Ltd (Binding Site) is a clinical diagnostic tools supplier that concentrates on research, development, manufacturing and distribution of immunodiagnostic assays. The company provides product portfolio such as antibodies, antigens, bulk antisera, assays for plasma prote …
  • Grupa Lotos SA (LTS)
    Grupa Lotos SA (LTS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • PolyPid Ltd:製品パイプライン分析
    Summary PolyPid Ltd (PolyPid) is a clinical stage pharmaceutical company that develops, manufactures and commercialize drugs for extended release and local delivery. The company develops its products using PLEX (Polymer-Lipid Encapsulation MatriX) platform, which helps in products. PolyPid’s pipelin …
  • Alnylam Pharmaceuticals Inc (ALNY):医療機器:M&Aディール及び事業提携情報
    Summary Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines, hepatic i …
  • Winbond Electronics Corporation (2344):企業の財務・戦略的SWOT分析
    Winbond Electronics Corporation (2344) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Harsoria Healthcare Pvt Ltd:企業の戦略的SWOT分析
    Harsoria Healthcare Pvt Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Nokia Corp (NOKIA):企業の財務・戦略的SWOT分析
    Nokia Corp (NOKIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Alamo Group, Inc.:企業の戦略・SWOT・財務情報
    Alamo Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Alamo Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Nynas AB:企業の戦略的SWOT分析
    Nynas AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Aeglea BioTherapeutics Inc (AGLE):企業の財務・戦略的SWOT分析
    Summary Aeglea BioTherapeutics Inc (Aeglea), formerly Aeglea BioTherapeutics Holdings, LLC is a biotechnology company. The company develops and commercializes human enzymes for the treatment of cancer and rare genetic diseases. The company’s lead product pipeline includes pegzilarginase (AEB1102), i …
  • Michael J Fox Foundation for Parkinson’s Research-医療機器分野:企業M&A・提携分析
    Summary Michael J Fox Foundation for Parkinson's Research (Michael J. Fox) is a research foundation that conducts research on Parkinson's disease. The foundation offers research and development of therapies. It provides drug development and other research activities in the area of Parkinson's diseas …
  • CMS Energy Corp (CMS):電力:M&Aディール及び事業提携情報
    Summary CMS Energy Corp (CMS Energy) is an energy utility which provides electricity, natural gas, and banking services. It generates, procures, transmits, distributes, and sells energy. The company produces power from coal, oil and gas, hydro, wind, and solar sources. CMS Energy purchases, transmit …
  • New York Independent System Operator Inc:企業の戦略的SWOT分析
    New York Independent System Operator Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆